Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study checks Brigatinib's performance in lung cancer

NCT ID NCT05735327

Ongoing Knowledge-focused Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Apr 15, 2026 · Last updated Jun 23, 2026 · Updated 9 times

Summary

This study follows 50 adults with ALK-positive non-small cell lung cancer who are taking brigatinib as their first treatment. Researchers want to see how long the cancer stays under control and how many patients respond to the drug. No new treatment is given; data is collected during regular hospital visits.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centrum Onkologii im.Prof. F. Lukaszczyka w Bydgoszczy

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland

  • Centrum Pulmonologii i Torakochirurgii w Bystrej

    Bystra, Slskie, 43-360, Poland

  • Dolnoslskie Centrum Onkologii, Pulmonologii i Hematologii

    Wroclaw, Dolnoslskie, 53-413, Poland

  • Instytut Gruzlicy i Chorob Pluc

    Warsaw, Masovian Voivodeship, 01-138, Poland

  • Krakowski Szpital Specjalistyczny im. Jana Pawla II w Krakowie

    Krakow, Lesser Poland Voivodeship, 31-202, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie, Panstwowy Instytut Badawczy

    Warsaw, Masovian Voivodeship, 02-781, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie- Panstwowy Instytut Badawczy Oddzial w Krakowie

    Krakow, Lesser Poland Voivodeship, 31-115, Poland

  • Podkarpackie Centrum Chorob Pluc

    Rzeszów, Podkarpackie Voivodeship, 35-241, Poland

  • SPZOZ Uniwersytecki Szpital Kliniczny nr 2 im. Wojskowej Akademii Medycznej Uniwersytetu Medycznego w Lodzi Centralny Szpital Weteranow

    Lodz, Łódź Voivodeship, 90-549, Poland

  • Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie

    Lublin, Lublin Voivodeship, 20-954, Poland

  • Szpital Kliniczny im. Heliodora Swiecickiego UM wPoznaniu.

    Poznan, Greater Poland Voivodeship, 60-355, Poland

  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu

    Poznan, Greater Poland Voivodeship, 60-569, Poland

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

brigatinib

What this could lead to

If successful, this study could confirm that brigatinib is effective in everyday clinical practice for ALK-positive lung cancer, supporting its continued use.

What could go wrong

This is an observational study, not a controlled trial, so results may be less reliable. It only includes 50 people and does not test a new treatment.

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC) NON-SMALL CELL LUNG CANCER (NSCLC)